Free Trial
→ My top 3 AI picks for the next decade (From The Oxford Club) (Ad)tc pixel
NASDAQ:RGEN

Repligen Q3 2026 Earnings Date & Estimates

Repligen logo
$173.88 0.00 (0.00%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$167.82 -6.06 (-3.48%)
As of 10/9/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Repligen is expected to report Q3 2026 earnings on Tuesday, November 3, 2026, before market opens. The conference call is scheduled for October 27, 2026 at 8:30 AM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call Date
Conference Call
8:30 AM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Repligen in Q3 2026

Repligen is expected to post earnings of $0.4604 per share on revenue of $206.73 million. In the same quarter a year earlier Repligen reported $0.46 per share on revenue of $188.81 million. Repligen last reported on July 28, 2026, posting $0.54 per share and beating the $0.4470 consensus estimate. Repligen has beaten the consensus EPS estimate in 7 of its last 8 quarters.

Consensus Estimates

Consensus EPS
$0.4604
Expected Revenue
$206.73 million
Prior-Year EPS
$0.46
Prior-Year Revenue
$188.81 million
Expected EPS Growth
+0.1%
Expected Revenue Growth
+9.5%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
$0.54 (Beat by +$0.0930)
Last Quarter Revenue
$204.13 million
EPS Beat Rate
7 of last 8 quarters

Prepare for the Q3 2026 Call

Repligen Q3 2026 Earnings FAQ

Repligen (NASDAQ:RGEN) is estimated to report Q3 2026 earnings on Tuesday, November 3, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Repligen's Q3 2026 earnings conference call is scheduled for Tuesday, October 27, 2026 at 8:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Repligen to post earnings of $0.4604 per share for Q3 2026.

The consensus revenue estimate for Repligen is $206.73 million for Q3 2026.

Repligen Earnings Headlines

Repligen Corp Completes Acquisition Of BioLife Solutions
October 7, 2026  |  rttnews.comhttps://www.rttnews.com/3697110/repligen-corp-completes-acquisition-of-biolife-solutions.aspx
Repligen Falls as Investors Digest BioLife Solutions Deal Closing
October 6, 2026  |  quiverquant.comQ
Elon says the ‘S’ word
Elon Musk and Sam Altman have sued each other and feuded for years. Yet within days of one another, both men described the same moment in strikingly similar terms: a technological tipping point they call the Singularity. James Altucher says the idea once belonged to science fiction. Now he connects it to a move Musk could make as soon as October 21, and lays out what both men see coming in a short presentation.tc pixel
 |  Paradigm Press (Ad)
Repligen Completes BioLife Acquisition to Expand Cell Therapies
October 6, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/repligen-completes-biolife-acquisition-to-expand-cell-therapies?utm_source=marketbeat.com&utm_medium=referral
BioLife Solutions Completes Repligen Merger and Nasdaq Delisting
October 6, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/biolife-solutions-completes-repligen-merger-and-nasdaq-delisting?utm_source=marketbeat.com&utm_medium=referral
Repligen Completes Acquisition of BioLife Solutions
October 6, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/06/3375610/24603/en/repligen-completes-acquisition-of-biolife-solutions.html
See More Repligen Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Repligen? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Repligen and other key companies, straight to your email.

About Repligen

Repligen (NASDAQ:RGEN) (NASDAQ:RGEN) develops and supplies bioprocessing technologies used by biopharmaceutical manufacturers to produce biological drugs, including monoclonal antibodies, recombinant proteins, vaccines and cell and gene therapies. Its products are used throughout the manufacturing process, from laboratory and process development through commercial-scale production.

The company’s portfolio includes chromatography products and protein A ligands and resins, filtration and fluid-management systems, single-use technologies, process analytics and other consumables and equipment. These solutions are designed to support purification, separation, monitoring and efficient handling of biological materials while helping biopharmaceutical producers improve manufacturing processes.

Founded in 1981, Repligen is headquartered in Waltham, Massachusetts, and serves biopharmaceutical and life sciences customers internationally. The company has expanded its offerings through internal development and acquisitions, including businesses focused on filtration, chromatography, single-use systems and process analytics. Tony J. Hunt has served as Repligen’s president and chief executive officer since 2015.

View Repligen Profile
Earnings Tools